What about radiotherapy for rectal cancer?
Abstract
Rectal cancer represents one of the most difficult oncological challenges due to its high risk of recurrence and multiple treatment complications. Recent decades have witnessed significant advances in the treatment of this malignancy, mainly due to the introduction of Total Mesorectal Excision and the use of perioperative radiation therapy and chemotherapy. Total mesorectal excision, developed in the 1980s, revolutionised rectal cancer surgery, significantly reducing local recurrence rates and improving treatment outcomes. Additionally, the implementation of both neoadjuvant and adjuvant perioperative radiation therapy has further reduced the risk of recurrence and improved patient survival. Complete neoadjuvant therapy (CNT) is gaining importance as an approach in the treatment of stage II-III rectal cancer. CNT combines chemoradiotherapy (ChRT) with chemotherapy before surgery and shows promising results. Phase II and III studies, such as RAPIDO and UNICANCER-PRODIGE 23, have shown that CNT leads to higher rates of complete pathological response, improves long-term survival (DFS), reduces early complications, and reduces the risk of local recurrence. However, it is not clear whether earlier chemotherapy or ChRT provides better results. Studies have also compared CNT with conventional therapies, indicating benefits in terms of treatment efficacy and lower toxicity. The paper discusses various approaches to perioperative management with a special focus on radiation therapy. It also presents recent clinical trials suggesting the possibility of further improvement of treatment outcomes by optimising combination therapy.